QuidelOrtho Q4 2022 preliminary revenue $853-868M; non-COVID rev up 18% proforma constant currency

QuidelOrtho Corp

2022-FY EPS reported $9.56 revenue$3,266,000,000

Preliminary Q4 total revenue $853M-$868M; COVID $124M-$134M; non-COVID $729M-$734M.
Non-COVID product revenue grew 485% GAAP, 18% proforma constant currency; driven by strong respiratory season.
Full year 2022 total revenue $4,038M-$4,053M; non-COVID $2,597M-$2,602M (11% proforma constant currency growth).
CEO Doug Bryant cited growth across Molecular Diagnostics, Transfusion Medicine, and Point of Care units.
Full earnings results and conference call scheduled for February 15, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

QuidelOrtho Corp reported the fourth quarter ended January 1, 2023 results: revenue $853 million to $868 million.

Period: the fourth quarter ended January 1, 2023
Revenue: $853 million to $868 million
Result: preliminary results

Exact text from the filing

The Company expects total revenues in the fourth quarter of 2022 to be in the range of $853 million to $868 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

QuidelOrtho Corp reported the full year ended January 1, 2023 results: revenue $4,038 million to $4,053 million.

Period: the full year ended January 1, 2023
Revenue: $4,038 million to $4,053 million
Result: preliminary results

Exact text from the filing

The Company expects total revenues in the full year of 2022 to be in the range of $4,038 million to $4,053 million.

View on SEC.gov

Browse all earnings releases →

QuidelOrtho Corp filing history →

Source: SEC EDGAR

accession 0001906324-23-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.